In8Bio Inc (INAB) Stock Price, Quote & News

Company Profile

IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its products include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product ca...

Industry: Biotechnology

Sector: Healthcare

Phone: 646 600 6438

Website: in8bio.com

Address:

350 5th Avenue, Suite 5330, New York, United States

_Volumetrix Dec. 8 at 11:52 PM

$BOLT $AEMD $INAB $OGEN $AGMH 4

0 · Reply

AndreaRR Dec. 6 at 9:01 AM

$INAB https://rheumnow.com/video/power-gamma-delta-t-cell-autoimmunity https://investors.in8bio.com/news-releases/news-release-details/in8bio-expands-inb-100 There are interesting developments, and they seem to be increasingly interesting for the scientific community. Of course, if a partnership is secured, it will be difficult to advance the pipeline financially. Institutional investors are still in "show me" mode. What gives me some hope is the forecast of a return of capital in the biotech sector, thanks to the likely rate cut, and the need for BP to obtain new potentially multi-billion dollar drugs, due to the approaching expiration of patents

1 · Reply

3ARated Dec. 3 at 10:35 AM

$INAB I haven’t found anything that says they are on the schedule.

1 · Reply

3ARated Dec. 2 at 2:58 PM

$INAB Who keeps kicking the legs out from under it?

1 · Reply

DARKP00L Nov. 24 at 8:13 PM

$INAB 14:53 on Nov. 24 2025 IN8bio Presents Consolidated INB-200 Phase 1 And INB-400 Phase 2 Glioblastoma Data At 2025 SNO Annual Meeting #tradeideas

0 · Reply

Kim0000 Nov. 24 at 7:09 PM

$INAB https://www.sec.gov/Archives/edgar/data/1740279/000119312525292057/0001193125-25-292057-index.htm

0 · Reply

CocaKolla Nov. 24 at 7:02 PM

$INAB on watch

0 · Reply

djotc Nov. 24 at 6:46 PM

$INAB nice bounce. Good news does deserve a nice run.

0 · Reply

TKKKKT Nov. 24 at 6:23 AM

$INAB 👀

0 · Reply

TWITLIEDETECTOR Nov. 17 at 5:25 AM

$INAB interesting place this companies in. above $1 but running on fumes with good up

0 · Reply

IN8bio Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Oct 29, 2025, 8:00 AM EDT - 5 weeks ago

IN8bio Expands INB-100 Phase 1 Clinical Trial with Addition of The Ohio State University as New Site

Oct 27, 2025, 8:00 AM EDT - 6 weeks ago

IN8bio Presents T cell Engager Data Demonstrating Deep B Cell Depletion for Autoimmune Indications

Aug 7, 2025, 4:26 PM EDT - 4 months ago

IN8bio (INAB) Q2 Loss Narrows 77%

Aug 7, 2025, 4:00 PM EDT - 4 months ago

IN8bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Jun 9, 2025, 7:00 AM EDT - 6 months ago

IN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblastoma Trial

Jun 2, 2025, 7:30 AM EDT - 6 months ago

IN8bio Presents Positive Phase 1 Data of INB-200 in Newly Diagnosed GBM Demonstrating Prolonged Progression-Free Survival

May 14, 2025, 8:00 AM EDT - 7 months ago

IN8bio Presents Preclinical Data Highlighting Potential of INB-619 T Cell Engager (TCE) for Autoimmune Disease at ASGCT 2025

May 12, 2025, 8:00 AM EDT - 7 months ago

IN8bio Presents Data at ISCT 2025 Demonstrating Proprietary γδ T cell Manufacturing Generates Consistent and Robust Clinical Products

May 7, 2025, 4:00 PM EDT - 7 months ago

IN8bio Reports First Quarter 2025 Financial Results and Recent Business Highlights

Apr 29, 2025, 8:00 AM EDT - 7 months ago

IN8bio to Present Clinical and Preclinical Data from Gamma-Delta T Cell Platform at Upcoming Scientific Conferences

Apr 28, 2025, 8:00 AM EDT - 8 months ago

IN8bio Unveils Promising New Data from Next Generation Gamma-Delta T Cell Engager (TCE) Platform at AACR 2025

Mar 31, 2025, 8:00 AM EDT - 9 months ago

IN8bio to Present New Preclinical Data on Novel Gamma-Delta (γδ) T cell Engager Platform for Cancer Immunotherapy at AACR Annual Meeting 2025

Mar 18, 2025, 8:05 AM EDT - 9 months ago

IN8bio to Participate at the 11th Annual Immuno-Oncology 360° Conference 2025

Mar 13, 2025, 4:05 PM EDT - 9 months ago

IN8bio Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights

Mar 3, 2025, 9:28 AM EST - 10 months ago

IN8bio Announces Advanced Gamma-Delta (γδ) T cell Engager (TCE) Platform for Oncology and Autoimmune Diseases

Feb 26, 2025, 8:00 AM EST - 10 months ago

IN8bio to Present at the TD Cowen 45th Annual Health Care Conference

Feb 24, 2025, 8:00 AM EST - 10 months ago

IN8bio to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

Feb 14, 2025, 9:00 AM EST - 10 months ago

IN8bio Presents Positive Phase 1 Data at TCT 2025, Highlighting Durability of Remissions in High-Risk AML

Feb 11, 2025, 8:00 AM EST - 10 months ago

IN8bio Reports Updated Positive Results from Phase 1 Trial of INB-100 in Leukemia Patients

Dec 10, 2024, 7:00 AM EST - 1 year ago

IN8bio Reports Continued Progression-Free Survival in Phase 1 Investigator-Sponsored Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 American Society of Hematology Annual Meeting

Nov 12, 2024, 4:26 PM EST - 1 year ago

IN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

Sep 4, 2024, 4:01 PM EDT - 1 year ago

IN8bio Announces Clinical Pipeline Prioritization to Focus on INB-100 for Acute Myeloid Leukemia

Aug 29, 2024, 6:05 AM EDT - 1 year ago

IN8bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 12, 2024, 8:05 AM EDT - 1 year ago

IN8bio Solidifies Position as a Clinical Leader of Gamma-Delta T Cell Therapy in Oncology with 100% of Treated AML Patients in Complete Remission and Receives FDA Guidance for Registrational Trial of INB-100

Jun 24, 2024, 8:00 AM EDT - 1 year ago

IN8bio to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

Jun 13, 2024, 4:01 PM EDT - 1 year ago

IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100

Jun 3, 2024, 6:05 AM EDT - 1 year ago

IN8bio Presents Progression-Free Survival Update from Phase 1 Study of INB-200 at 2024 American Society of Clinical Oncology Annual Meeting

May 24, 2024, 8:00 AM EDT - 1 year ago

IN8bio to Present at International Society for Cell & Gene Therapy (ISCT) 2024

May 23, 2024, 5:00 PM EDT - 1 year ago

IN8bio Announces INB-200 Phase 1 Study Data in Newly Diagnosed Glioblastoma to be Presented at the 2024 ASCO Annual Meeting

May 14, 2024, 10:00 AM EDT - 1 year ago

IN8bio Announces Upcoming Presentation at 2024 European Hematology Association Congress

May 13, 2024, 8:00 AM EDT - 1 year ago

IN8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation at ASGCT 2024

May 9, 2024, 4:00 PM EDT - 1 year ago

IN8bio Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

Apr 30, 2024, 6:05 AM EDT - 1 year ago

IN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed Glioblastoma

Apr 24, 2024, 8:00 AM EDT - 1 year ago

IN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

Apr 16, 2024, 4:05 PM EDT - 1 year ago

IN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference

Apr 9, 2024, 4:30 PM EDT - 1 year ago

IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024

Mar 14, 2024, 4:00 PM EDT - 1 year ago

IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights

Mar 5, 2024, 4:30 PM EST - 1 year ago

IN8bio to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024

Feb 26, 2024, 8:00 AM EST - 1 year ago

IN8bio to Present at Upcoming Investor Conferences

Feb 14, 2024, 8:00 AM EST - 1 year ago

IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology

Jan 4, 2024, 8:00 AM EST - 2 years ago

IN8bio Highlights Recent Company Accomplishments and Outlines 2024 Pipeline Goals

Dec 11, 2023, 4:05 PM EST - 2 years ago

IN8bio Announces Positive Clinical Update Demonstrating Continued Durable Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 in Leukemia

Dec 11, 2023, 9:00 AM EST - 2 years ago

IN8bio Announces Pricing of Financing Totaling up to $46.9 Million in Private Placement

Dec 7, 2023, 8:00 AM EST - 2 years ago

IN8bio Appoints Dr. Corinne Epperly to Board of Directors

Dec 5, 2023, 8:00 AM EST - 2 years ago

IN8bio to Host Investor Call at 8:30 AM ET on Tuesday, December 12 to Discuss Updated Clinical Data from Phase 1 Trial of INB-100 in Patients with Leukemia

Nov 20, 2023, 7:00 AM EST - 2 years ago

IN8bio's INB-200 Demonstrates Extended Progression-Free Survival in Patients with Newly Diagnosed Glioblastoma

Nov 10, 2023, 7:00 AM EST - 2 years ago

IN8bio to Present Data Highlighting Potential of INB-200 and INB-400 to Treat Patients with Newly Diagnosed Glioblastoma Multiforme at Society for Neuro-Oncology 28th Annual Meeting

Nov 9, 2023, 4:00 PM EST - 2 years ago

IN8bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 6, 2023, 8:00 AM EST - 2 years ago

IN8bio Presents Biologic Correlative Data from the INB-200 Phase 1 Trial in Newly Diagnosed Glioblastoma at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

_Volumetrix Dec. 8 at 11:52 PM

$BOLT $AEMD $INAB $OGEN $AGMH 4

0 · Reply

AndreaRR Dec. 6 at 9:01 AM

1 · Reply

3ARated Dec. 3 at 10:35 AM

$INAB I haven’t found anything that says they are on the schedule.

1 · Reply

3ARated Dec. 2 at 2:58 PM

$INAB Who keeps kicking the legs out from under it?

1 · Reply

DARKP00L Nov. 24 at 8:13 PM

$INAB 14:53 on Nov. 24 2025 IN8bio Presents Consolidated INB-200 Phase 1 And INB-400 Phase 2 Glioblastoma Data At 2025 SNO Annual Meeting #tradeideas

0 · Reply

Kim0000 Nov. 24 at 7:09 PM

$INAB https://www.sec.gov/Archives/edgar/data/1740279/000119312525292057/0001193125-25-292057-index.htm

0 · Reply

CocaKolla Nov. 24 at 7:02 PM

$INAB on watch

0 · Reply

djotc Nov. 24 at 6:46 PM

$INAB nice bounce. Good news does deserve a nice run.

0 · Reply

TKKKKT Nov. 24 at 6:23 AM

$INAB 👀

0 · Reply

TWITLIEDETECTOR Nov. 17 at 5:25 AM

$INAB interesting place this companies in. above $1 but running on fumes with good up

0 · Reply

BigTimePennyStocks Nov. 17 at 12:45 AM

Small-Caps with Catalysts this week: 👇👇 ( $ATOS, $AEON, $INAB, $AIRE, $RVYL, etc...) #NASDAQ #NYSE

1 · Reply

ZekeBalderdash Nov. 12 at 4:37 PM

$INAB Digging in a little more, it seems very unlikely to me that the GBM data will be a turning point. The update would have to show significantly better results than the early data to de-risk the investment enough for big pharma in the current environment. Good enough to merit continuation, almost certainly, but not enough to make a partnership likely. The AML data stand a real chance of being transformative, but will they publish before running out of money? Will they find some funding that isn't horrifically dilutive to get them there? They're on a knife edge.

0 · Reply